Low-density lipoprotein cholesterol (LDL-C) is a traditional and important risk factor for atherosclerotic cardiovascular disease (CVD). Recently, lipoprotein (a) (lp(a)) attracts considerable attention as a residual risk factor for CVD. However, the roles of lp(a) in acute coronary syndrome (ACS) patients with well-controlled LDL-C (≤1.8mmol/L) after percutaneous coronary intervention (PCI) remain unclear. Current study results demonstrated that occurrence of major adverse cardiovascular events (MACE) and recurrent myocardial infarction (MI) increased with the Lp(a) increasing in patients with LDL-C≤1.8mmol/L at 1-month follow-up. In relatively low-risk patients presented with ACS and underwent PCI (LDL-C ≤1.8mmol/L at 1-month follow-up), lp(a) is still independently related to adverse prognosis. Further researches of targeted therapy against lp(a) are warranted.

低密度脂蛋白胆固醇 (LDL-C) 是动脉粥样硬化性心血管疾病 (CVD) 的传统且重要的危险因素。最近，脂蛋白 (a) (lp(a)) 作为 CVD 的残余危险因素引起了相当多的关注。然而，lp(a) 在经皮冠状动脉介入治疗 (PCI) 后 LDL-C (≤1.8mmol/L) 控制良好的急性冠状动脉综合征 (ACS) 患者中的作用仍不清楚。目前的研究结果表明，在随访1个月时，LDL-C≤1.8mmol/L患者的主要不良心血管事件（MACE）和复发性心肌梗死（MI）的发生率随着Lp（a）的升高而增加。在出现 ACS 并接受 PCI 的相对低风险患者中（1 个月随访时 LDL-C ≤1.8 mmol/L），lp(a) 仍与不良预后独立相关。